The Theranos scandal was one of the largest corporate fraud cases in American history. Elizabeth Holmes, a Stanford dropout, founded a blood-testing startup that claimed to run hundreds of diagnostic tests from just a few drops of blood. The technology never worked as promised, but Holmes raised over $700 million from investors and pushed the company to a peak valuation of $9 billion before it all collapsed.
What Theranos Claimed to Do
Holmes founded Theranos in 2003, at age 19, with a bold vision: replace the standard needle-in-the-arm blood draw with a painless fingertip prick that could fill a tiny vial and run a wide menu of diagnostic tests. The company’s proprietary device, called the Edison, was supposed to make lab work faster, cheaper, and less intimidating. Theranos marketed over 200 tests to consumers.
The promise was compelling enough to attract a board of directors stacked with former secretaries of state, military leaders, and U.S. senators. Holmes became a media sensation, appearing on magazine covers and drawing comparisons to Steve Jobs. By 2014, the company was valued at $9 billion, making Holmes the youngest self-made female billionaire on paper.
What Was Actually Happening in the Lab
The Edison device was only ever used for about 12 of the more than 200 tests Theranos offered. For the rest, the company relied on conventional lab machines purchased from established manufacturers like Siemens. To make these standard machines work with the tiny finger-prick samples, Theranos diluted the blood to increase its volume. Dilution introduces more potential for error, because tiny measurement inaccuracies get magnified when the sample is stretched.
Former employees later revealed that the company wasn’t running many of its advertised tests on Edison devices at all. Test reports sent to patients listed the company’s Newark, California lab as the testing site, where both Edison devices and traditional machines sat side by side. But the traditional machines were doing the heavy lifting, and the diluted samples were producing unreliable results. Holmes publicly denied that Theranos diluted blood samples, even as internal evidence mounted.
The Walgreens Partnership
Theranos didn’t just sell its story to investors. It brought its unreliable testing directly to consumers through a retail partnership with Walgreens, which opened 40 Theranos “wellness centers” in Arizona where everyday customers could walk in and order blood tests. This gave the company a veneer of mainstream credibility and put inaccurate diagnostics in front of real patients making real health decisions.
Walgreens terminated the relationship in 2016, closing all 40 locations immediately. By that point, federal regulators had already flagged major problems at the company’s California lab, and the damage to patients was becoming impossible to ignore.
How Patients Were Harmed
The consequences went far beyond lost investor money. Theranos equipment produced inaccurate results on roughly one in every ten tests. Across an estimated 890,000 test results generated each year, that meant tens of thousands of people received wrong information about their health. Patient stories of emotional trauma following false cancer diagnoses were disturbingly common. Some people underwent unnecessary medical procedures or experienced severe anxiety based on results that turned out to be meaningless.
Treatment decisions made from faulty diagnostics can be dangerous and even life-threatening. A falsely normal result might cause someone to skip treatment they need, while a false positive could lead to invasive follow-up testing, medications with real side effects, or psychological harm that lingers long after the correction. Theranos eventually voided blood test results for tens of thousands of patients, but by then many had already acted on the incorrect information.
How the Fraud Unraveled
The unraveling began in 2015, when a series of Wall Street Journal investigations by reporter John Carreyrou exposed the gap between what Theranos claimed and what its technology actually did. Carreyrou’s reporting, sourced heavily from former employees turned whistleblowers, revealed that the Edison device couldn’t deliver on its promises and that the company was running most tests on conventional equipment with diluted samples.
Federal regulators from the Centers for Medicare and Medicaid Services inspected the company’s labs and found serious deficiencies. The Securities and Exchange Commission opened an investigation into whether Holmes and her business partner, Ramesh “Sunny” Balwani, had misled investors. In 2016, Theranos began voiding two years’ worth of test results. By 2018, Holmes stepped down as CEO, and the company officially ceased operations.
Criminal Convictions and Prison Sentences
In June 2018, a federal grand jury indicted both Holmes and Balwani on two counts of conspiracy to commit wire fraud and nine counts of wire fraud. Their trials were held separately.
In January 2022, a jury convicted Holmes on one count of conspiracy to commit fraud against investors and three counts of investor fraud involving wire transfers totaling more than $140 million. She was acquitted on the patient-related fraud charges. A judge sentenced her to 11 years and 3 months in federal prison.
Balwani’s trial resulted in broader convictions. He was found guilty of fraud that both deceived investors and endangered patients by misrepresenting the accuracy of Theranos technology. His sentence was harsher: 12 years and 11 months in federal prison.
Why the Scandal Mattered Beyond Theranos
The Theranos case exposed how a charismatic founder, a prestigious board, and aggressive media coverage could substitute for actual scientific validation. Holmes raised hundreds of millions of dollars from sophisticated investors, including wealthy families and venture capital funds, without ever submitting her technology to independent peer review or publishing results in scientific journals. The company operated in a regulatory gap where laboratory-developed tests faced less scrutiny than devices sold to other labs or hospitals.
The scandal also damaged public trust in health innovation at a vulnerable time. Patients who received false results from Theranos had reason to doubt diagnostic testing more broadly, a problem that researchers noted became especially relevant during the COVID-19 pandemic, when public confidence in testing was critical. The case prompted calls for stricter oversight of laboratory-developed tests and greater transparency from health technology startups making bold clinical claims.